Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026764 (
multiple myeloma
)
36,148
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cinobufagin
(
CBG
) is a cardiotoxic bufanolide steroid secreted by the skin and parotid venom glands of the Asiatic toad Bufo bufo gargarizans (called Chan-Su). Although
CBG
is known to exhibit anti-cancer activities, very little is known about its potential mechanism(s) of action. In this study, we investigated whether
CBG
mediates its effect through the modulation of the mitogen-activated protein kinases (MAPKs) signaling pathway in human
multiple myeloma
(MM) U266 cells. We found that
CBG
caused the significant activation of ERK, JNK and p38 MAPK in U266 cells.
CBG
showed much higher cytotoxicity against U266 cells as compared to peripheral blood mononuclear cells (PBMC). Induction of
CBG
increased reactive oxygen species (ROS) generation from mitochondria, which is associated with the induction of apoptosis as characterized by increased sub-G1 DNA contents of cell cycle, positive Annexin V binding, activation of caspase-3 and cleavage of PARP. Inhibition of ROS generation by N-acetyl-l-cysteine (NAC) significantly prevented
CBG
-induced ERK, JNK and p38 MAPK activation and apoptosis.
CBG
also down-regulated the expression of various downstream gene products that mediate cell proliferation, survival, angiogenesis and metastasis. Interestingly, ERK, JNK and p38MAPK pharmacological inhibitors blocked
CBG
-induced MAPKs activation and ERK inhibitor (PD98059) also prevented the
CBG
-induced caspase-3 activation and PARP cleavage in U266 cells. Taken together, these findings suggest that
CBG
can act as a potent anticancer agent against MM and possibly exerts its effects through the ROS-mediated activation of ERK, JNK and p38 MAPK leading to the activation of caspase-3 in U266 cells.
...
PMID:Cinobufagin exerts anti-proliferative and pro-apoptotic effects through the modulation ROS-mediated MAPKs signaling pathway. 2598 94